drugset / Trial / NCT05845645

A Study to Test Bioavailability of of 2 New Formulations of UCB0599 in Healthy Participants in Part A and to Test Safety, Tolerability, and Pharmacokinetic (PK) of UCB0599 in Healthy Japanese and Chinese Participants in Part B

NCT05845645

Phase 1 Completed 73 enrolled UCB Biopharma SRL
RandomizedCrossoverQuadruple-blindBasic science

Summary

The purpose of the study is to estimate the relative bioavailability of 2 new UCB0599 formulations under elevated and normal gastric pH conditions in healthy participants (Part A) and to asess the safety, tolerability and pharmacokinetics of UCB0599 in healthy participants of Japanese and Chinese origins (Part B).

Timeline

Start
2023-05-31
Primary completion
2024-04-13
Completion
2024-04-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Esomeprazole Small molecule Oral
Subject Minzasolmin Small molecule Oral

Indications

No indication recorded.